Show simple item record

dc.contributor.authorSoto, A.
dc.contributor.authorQuiñones-Laveriano, D.M.
dc.contributor.authorAzañero, J.
dc.contributor.authorChumpitaz, R.
dc.contributor.authorClaros, J.
dc.contributor.authorSalazar, L.
dc.contributor.authorRosales, O.
dc.contributor.authorNuñez, L.
dc.contributor.authorRoca, D.
dc.contributor.authorAlcantara, A.
dc.date.accessioned2025-10-31T18:37:35Z
dc.date.available2025-10-31T18:37:35Z
dc.date.issued2022
dc.identifier.urihttps://hdl.handle.net/20.500.12805/5537
dc.description.abstractObjectives To determine the risk factors for in-hospital mortality in patients with COVID-19 from a Peruvian national hospital. Methods Retrospective cohort study of medical records of patients with COVID-19 hospitalized at Hospital Nacional Hipo lito Unanue (HNHU) during the months of April to August 2020. The dependent variable was in-hospital mortality. Independent variables included sociodemographic and clinical characteristics, physical examination findings, oxygen saturation (SaO2) at admission, treatment received during hospitalization and laboratory results at admission. A Cox regression model was used to evaluate the crude and adjusted hazard ratios for associated factors. Results We included 1418 patients. Median age was 58 years (IQR 47-68 years) and 944 (66.6%) were male. The median length of hospitalization was 7 (4-13) days, and the mortality rate was 46%. The most frequent comorbidities were type 2 diabetes mellitus, hypertension, and obesity. In the adjusted analysis, mortality was associated with age (HR 1.02; 95%CI 1.02- 1.03), history of surgery (HR 1.89; 95%CI 1.31-2.74), lower oxygen saturation at admission (HR 4.08; CI95% 2.72-8.05 for SaO2<70% compared to SaO2>94%), the presence of poor general condition (HR 1.81; 95% CI 1.29-2.53), altered state of consciousness (HR 1.58; 95%CI 1.18-2.11) and leukocyte levels (HR 1.01; 95%CI 1.00-1. 02). Treatment with ivermectin (HR 1.44; 95%CI 1.18-1.76) and azithromycin (HR 1.25; 95%CI 1.03-1.52) were associated with higher mortality. Treatment with corticosteroids at low to moderate doses was associated with lower mortality (HR 0.56 95%CI 0. 37-0. 86) in comparison to no steroid use. Conclusion A high mortality was found in our cohort. Low oxygen saturation at admission, age, and the presence of hematological and biochemical alterations were associated with higher mortality. The use of hydroxychloroquine, ivermectin or azithromycin was not useful and was probably associated with unfavorable outcomes. The use of corticosteroids at moderate doses was associated with lower mortality.en_US
dc.formatapplication/pdf
dc.language.isoeng
dc.publisherPublic Library of Science
dc.relation.ispartofurn:issn:1932-6203
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectSDG 3en_US
dc.subjectCOVID-19, Its Impact, and Vaccinationen_US
dc.subjectClinical Insights into COVID-19 Patient Outcomesen_US
dc.titleMortality and associated risk factors in patients hospitalized due to COVID-19 in a Peruvian reference hospitalen_US
dc.typehttps://purl.org/coar/resource_type/c_2df8fbb1
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0264789
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.00.00
dc.type.otherResearch article
dc.identifier.journalPLoS ONE
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2